Preferred Name

Ilorasertib

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116729

CAS_Registry

1227939-82-3

code

C116729

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

GDC

FDA

DEFINITION

An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.

Display_Name

Ilorasertib

FDA_UNII_Code

6L5D03D975

FULL_SYN

A-968660.0

ILORASERTIB

1-(4-(4-Amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea

Ilorasertib

ABT-348

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C30006

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17293

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C68596

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C95267

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17322

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Ilorasertib

Maps_To

Ilorasertib

NCI_Drug_Dictionary_ID

672556

PDQ_Closed_Trial_Search_ID

672556

PDQ_Open_Trial_Search_ID

672556

Preferred_Name

Ilorasertib

prefixIRI

Thesaurus:C116729

prefLabel

Ilorasertib

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C3660880

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/MESH/C577638 Medical Subject Headings / 医学主题词表 LOOM